SBIR Phase I: Dendrimer-Immobilized Antibody Kits for the Detection of Bioterror Pathogens

SBIR 第一阶段：用于检测生物恐怖病原体的树枝状大分子固定化抗体试剂盒

• 批准号: 0318842
• 负责人: Charles Spangler
• 金额: $ 10万
• 依托单位: SENSOPATH TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-01 至 2003-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0318842&HistoricalAwards=false
• 关键词: SBIR; Phase; Dendrimer; Immobilized; Antibody

This Small Business Innovation Research (SBIR) Phase I project is to develop rapid detection protocols for bioterror-related pathogens. At the current time, there are no simple and inexpensive recognition systems that are well suited to the simultaneous detection of multiple pathogenic agents. This is particularly true for first responders at the point of attack, such as police, paramedics, and firefighters. Since exposure to Class A bioterror pathogens causes flu-like symptoms in their victims during the first few days after exposure, it is critical that the pathogen be identified as quickly as possible (that is, in one to four hours) in order to minimize fatalities. In this project, a unique biorecognition system based on immobilized antibodies to a variety of protein toxins will be developed. Fluorophores will be attached to multi-branched dendrimers that are also derivatized for immobilization of antibodies against bioterror pathogens. The detection ensemble will be in a kit form, with easy to follow instructions for the identification of specific pathogens by antibody-antigen binding, using chromatographic separation and fluorescence detection of the complex. It is anticipated that a typical protocol starting from samples obtained at the point of attack will be able to identify a wide variety of bioterror agents in 1 to 4 hours.The main commercial application of this project will be for first responders involved in Homeland Defense. Additional applications are expected in the food and beverage industry, biomedical research laboratories, water treatment facilities and medical diagnostics companies.

这个小型企业创新研究(SBIR)第一阶段项目是开发与生物恐怖相关的病原体的快速检测协议。目前，还没有一种简单、廉价的识别系统可以很好地同时检测多种病原体。对于受到攻击的第一反应人员，如警察、护理人员和消防员，情况尤其如此。由于接触A类生物恐怖病原体会在接触后的最初几天内导致受害者出现流感样症状，因此尽快(即在一到四个小时内)确定病原体是至关重要的，以将死亡人数降至最低。在这个项目中，将开发一种独特的生物识别系统，该系统基于对各种蛋白质毒素的固定化抗体。荧光团将被连接到多支化的树状大分子上，这些树状大分子也是衍生的，用于固定针对生物恐怖病原体的抗体。检测组合将以试剂盒的形式存在，易于遵循说明，通过抗体-抗原结合、使用色谱分离和复合体的荧光检测来识别特定病原体。预计一个典型的方案，从攻击点获取的样本开始，将能够在1到4小时内识别出各种生物恐怖毒剂。该项目的主要商业应用将是国土防务的第一反应人员。预计在食品和饮料行业、生物医学研究实验室、水处理设施和医疗诊断公司还会有更多的应用。